Pbi13 Trends in List Prices, Net Prices, and Discounts of Self-Administered Tumor Necrosis Factor Inhibitors

Abstract

Objectives: To describe trends in list prices, net prices, and discounts for selfadministered disease-modifying therapies (DMTs) for multiple sclerosis (MS) from 2007-2019. Methods: We obtained 2007-2019 pricing data for dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1A, interferon beta-1B, peginterferon beta-1A, and teriflunomide from SSR Health, which provides quarterly estimates of list prices, net prices, and discounts in Medicaid and other payers for branded products manufactured by publicly traded companies. For each drug and year, we calculated average list and net annual costs of treatment based on FDA-approved dosing; and average discounts in Medicaid and other payers. Results: From 2007-2019, list prices of self-administered MS DMTs increased by 4.